Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamorelin to prevent weight loss after pancreaticoduodenectomy
jRCTs041230138Recruiting
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of anamorelin in pancreatic cancer (PC) and None (2 arms). Primary endpoint: Percentage of postoperative weight loss compared to preoperative weight. Started Feb 2024; status: recruiting.
02
Drugs
anamorelin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs041230138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041230138.